Theratechnologies Highlights The Impact Of Excess Visceral Abdominal Fat On Cardiovascular Disease Risk In People With HIV At IDWeek 2024

Benzinga · 10/17 18:01

Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced data from two poster presentations, focusing on the association between excess visceral abdominal fat (EVAF) and cardiovascular disease (CVD) risk in people with HIV (PWH), and on the use of tesamorelin to reduce such risk.

In a poster presentation at IDWeek 2024 in Los Angeles, Calif., investigators from the Visceral Adiposity Measurement and Observations Study (VAMOS) reported that EVAF is one of several risk factors that contribute to heightened CVD risk in PWH who are on modern anti-retroviral therapy (ART) regimens. In a separate poster presentation, researchers demonstrated that the EVAF-lowering properties of tesamorelin, a growth hormone-releasing factor (GHRF), enable a reduction in CVD risk in PWH.